{"organizations": [], "uuid": "7add8c1e590ec826dab40b8c90eeea4ddc8643f0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/26/globe-newswire-progenics-pharmaceuticals-sets-first-quarter-2018-financial-results-call-for-may-9.html", "country": "US", "domain_rank": 767, "title": "Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.949, "site_type": "news", "published": "2018-04-26T16:30:00.000+03:00", "replies_count": 0, "uuid": "7add8c1e590ec826dab40b8c90eeea4ddc8643f0"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/26/globe-newswire-progenics-pharmaceuticals-sets-first-quarter-2018-financial-results-call-for-may-9.html", "ord_in_thread": 0, "title": "Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9", "locations": [], "entities": {"persons": [], "locations": [{"name": "new york", "sentiment": "none"}], "organizations": [{"name": "progenics pharmaceuticals", "sentiment": "negative"}, {"name": "progenics pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "progenics", "sentiment": "none"}, {"name": "psma ttc", "sentiment": "none"}, {"name": "progenics progenics", "sentiment": "none"}, {"name": "media center", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2018 financial results on Wednesday, May 9, 2018 at 8:30 a.m. ET.\nTo participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 3564709. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com , and a replay will be available for two weeks.\nAbout Progenics\nProgenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA ® , 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics' first commercial product, RELISTOR ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.\nThis press release may contain projections and other \"forward-looking statements\" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as \"anticipate,\" \"believe,\" \"plan,\" \"could,\" \"should,\" \"estimate,\" \"expect,\" \"forecast,\" \"outlook,\" \"guidance,\" \"intend,\" \"may,\" \"might,\" \"will,\" \"possible,\" \"potential,\" \"predict,\" \"project,\" or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations; the unpredictability of the duration and results of regulatory review of New Drug Applications (NDA) and Investigational NDAs, including our NDA for AZEDRA; market acceptance for approved products; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission, including those risk factors included in its Annual Report on Form 10-K for the annual period ended December 31, 2017. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.\nAdditional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com . Information on or accessed through our website or social media sites is not included in the company's SEC filings.\n(PGNX-F)\nContact :\nMelissa Downs\nInvestor Relations\n(646) 975-2533\nmdowns@progenics.com\nSource:Progenics Pharmaceuticals Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/23fd2682-25c5-435e-9ecf-6a3079ca6226"], "published": "2018-04-26T16:30:00.000+03:00", "crawled": "2018-04-26T17:28:42.004+03:00", "highlightTitle": ""}